Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113 CHF | +15.31% | -.--% | +15.31% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The firm trades with high earnings multiples: 24.7 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.74 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.31% | 24.72B | - | ||
-6.04% | 181B | C+ | ||
+2.88% | 114B | C | ||
-3.17% | 68.29B | A | ||
+4.80% | 52.24B | B- | ||
+7.72% | 44.3B | B- | ||
+6.67% | 42.73B | B+ | ||
+25.69% | 32.52B | B | ||
+20.03% | 26.02B | A- | ||
-1.27% | 25.91B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZBH Stock
- ZBH Stock
- Ratings Zimmer Biomet Holdings, Inc.